Agenda will run 08.20-18.00 CET

8:00 am Virtual Coffee Networking Morning Round Two!

8:20 am Chair’s Opening Remarks

Innovations in Biomarker-Driven Clinical Trials: Key Learnings & Insights to Shape Future Drug-Dx Strategy

8:30 am Biomarker-Driven & Diagnostic Enabled Trials – Managing the Expanding Complexity and Application Outside Oncology

  • Rob Hastings Precision Medicine Expert, Cardiovascular, Renal and Metabolism, AstraZeneca

Synopsis

  • Review the current position and trends in the development of companion diagnostics e.g. complex markers and growth in nononcology indications
  • Key challenges and opportunities for CDx development outside oncology
  • Share examples of early work for planning commercialisation of nononcology diagnostics – a pharma perspective

9:00 am HalioDx and the Development of an Integrated Multi-Omic Approach to Interrogating the Tumor Microenvironment and CDx Development

  • Corinne Dannan Executive Vice President, Pharma BU, Board Member, HalioDx

Synopsis

• Integration and interpretation of multi-omic data sets is key to the success of any I/O research program, HalioDx has developed new tools to streamline this process
• Immunogram and ATLAS together provide the foundation to visualize and interpret complex data sets into actionable paths for patients and clinical trial programs
• Biomarker signatures are readily identified from multitude of platforms (mIHC, NGS, RNAish, etc.) and provide key insights into potential CDx/Dx opportunities

9:30 am Virtual Exhibition Hall Break

Synopsis

  •  Visit our meeting partner’s virtual exhibitions and you might virtually walk away having met your next partner!
  • With videos and real time discussion alongside your peers, there’s plenty to get involved with in this interactive break

10:00 am Panel Discussion: Hemato-Oncology: can we turn MRD into a new opportunity for CDx and beyond?

  • Luca Quagliata Global Head of Medical Affairs, Thermo Fisher Scientific
  • Lawrence Weiss Chief Scientific Officer, NeoGenomics Laboratories
  • Megan Lim Professor of Pathology and Laboratory Medicine, Director of Hematopathology, University of Pennsylvania

11:15 am The Use of Combination Biomarkers & Combination Medications to Treat Nonalcoholic Steatohepatitis (NASH): The Combo-Combo Approach

  • Naim Alkhouri Director, Fatty Liver Program, Vice President of Academic Affairs, Arizona Liver Health

Synopsis

  • Describe current biomarkers and therapeutic agents for nonalcoholic steatohepatitis
  • Looking at the Phase II proof-of-concept trial alongside Gilead & NovoNordisk (utilising exploratory biomarker endpoints)
  • Insight to shape future clinical strategy based on clinical findings & data

11:45 am Final Speed Networking Break

1:15 pm Networking Lunch

Synopsis

Whilst enjoying a bite to eat, you can take part in:

121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the biomarker-driven drug development space
Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward

3:00 pm Networking Break

Synopsis

Whilst enjoying a bite to eat, you can take part in:

  • 121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the biomarker-driven drug development space
  • Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward

3:30 pm Panel Discussion: A Multi-Stakeholder View: Enabling the Delivery Of Next Gen Precision Therapies With Robust Biomarker Plans

  • John Armstrong Global Head of Discovery, Galderma International
  • Bridget Bannerman Translational Science, Theoretical Systems Biology & Global health Researcher, MRC Laboratory of Molecular Biology
  • Hiromasa Mori Medical Devices Neurology Patient Technology, UCB S.A.
  • Jinyu Shan Research Fellow & Chief Scientific Officer , University of Leicester

Synopsis

  • What has the last 12 months shown is driving the delivery of precision medicine
  • What is on the horizon?
  • Analytical advancements powering biomarker development for accelerated drug development
  • What has real world uptake shown for the future commercial viability and widespread adoption of Rx-Dx in the EU market
  • Finding patient-centric tools enabling clinicians to act despite complex biomarker profiles
  • How technologies, including multiplexing, enable the collection of more precise information

4:00 pm Liquid Biopsy: Improving Access for Cancer Patients Globally

  • Ian Walker Vice President, International , Guardant Health

Synopsis

• Liquid biopsy is increasing access to the right medicines for many patients
• Significant regulatory and reimbursement hurdles remain for global access, but progress is being made
• Further platform advances offer opportunities across the continuum of care

4:30 pm Biomarkers from Exploratory to Clinical Trials to Companion Diagnostics: Advantages of Planning Early

Synopsis

• Selection of biomarker technology to correspond with intended use in a clinical trial
• Paths from exploratory biomarkers: Test results as inclusion criteria in clinical trials
• A few emerging biomarker technologies

5:00 pm Moving Omics-based Diagnostic Workflows into Clinical Healthcare

  • Alain Van Gool Head Translational Metabolic Laboratory, Department Laboratory Medicine , Radboudumc

Synopsis

• Technology innovation is driving impact in personalized healthcare
• It is crucial to combine different molecular views to understand human health and disease (X-omics)
• Fast translational of biomarker research to implementation in academic clinical laboratories
• Clinical demonstrators and open data science lead the way

5:30 pm Chair’s Closing Remarks & End of Day Two: Close of the 11th Clinical Biomarkers & World CDx Europe Summit 2021

  • Mila Glavaski Data Science & Machine Learning in Medicine , Independent Consultant

Synopsis

We hope you enjoyed this year’s virtual summit and look forward to hearing on where your exciting work takes you for 2022!

Bonus Content

AI in Precision Medicine

  • Chris Rowe Innovation Lead - Precision Medicine, Innovate UK

Synopsis

• Innovate UK perspective on AI
• The role of AI and data access
• Digital pathology, imaging and AI Centres of Excellence